MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Затворен

СекторЗдравеопазване

2.68 -1.47

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.67

Максимум

2.73

Ключови измерители

By Trading Economics

Приходи

-5.9M

247K

Продажби

5.1M

62M

Марж на печалбата

0.395

Служители

181

EBITDA

-6.1M

7.4M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+156.41% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-162M

726M

Предишно отваряне

4.15

Предишно затваряне

2.68

Настроения в новините

By Acuity

94%

6%

356 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Akebia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.09.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30.09.2025 г., 23:43 ч. UTC

Горещи акции

Stocks to Watch: GEO Group, Lithium Americas, Nike

30.09.2025 г., 23:12 ч. UTC

Печалби

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30.09.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30.09.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Lifeway Foods, Danone Agree to Stay Litigation

30.09.2025 г., 21:17 ч. UTC

Печалби

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30.09.2025 г., 20:47 ч. UTC

Печалби

Nike 1Q Sales Rise as Turnaround Progresses

30.09.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30.09.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30.09.2025 г., 23:26 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30.09.2025 г., 23:26 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30.09.2025 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30.09.2025 г., 23:24 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30.09.2025 г., 23:24 ч. UTC

Придобивния, сливания и поглъщания

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30.09.2025 г., 22:54 ч. UTC

Пазарно говорене

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30.09.2025 г., 22:38 ч. UTC

Печалби

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30.09.2025 г., 22:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.09.2025 г., 22:32 ч. UTC

Пазарно говорене

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30.09.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30.09.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30.09.2025 г., 21:02 ч. UTC

Печалби

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

30.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.09.2025 г., 20:28 ч. UTC

Печалби

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30.09.2025 г., 20:22 ч. UTC

Печалби

Nike 1Q North America Revenue $5.02B >NKE

30.09.2025 г., 20:22 ч. UTC

Печалби

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30.09.2025 г., 20:22 ч. UTC

Печалби

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30.09.2025 г., 20:22 ч. UTC

Печалби

Nike 1Q Greater China Revenue $1.51B >NKE

30.09.2025 г., 20:19 ч. UTC

Печалби

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Сравнение с други в отрасъла

Ценова промяна

Akebia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

156.41% нагоре

12-месечна прогноза

Среден 7 USD  156.41%

Висок 8 USD

Нисък 6 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Akebia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

2.345 / N/AПодкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

356 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat